JW (Cayman) Therapeutics Co. Ltd (the “Company”) is a global leading clinical stage cell therapy platform company. The Company’s vision is to develop best-in-class and/or first-in-class cell therapies for the China market to transform the treatment of cancer for Chinese patients. Since the establishment of JW Shanghai in 2016 , it has built an integrated platform focused on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors.


The company is a pioneer in China for the development of cell-based immunotherapy, a field which represents a paradigm shift and the latest advancement in the treatment of cancer. Cell-based immunotherapies, including CAR-T treatments, are an innovative treatment method that uses human immune cells to fight cancer. Supported by multiple clinical studies, cell-based immunotherapies could lead to long-lasting remissions of B-cell lymphomas and leukemias which are refractory to other treatments.


Relmacabtagene autoleucel (“relma-cel”), its lead product candidate, is an anti-CD19 CAR-T therapy for relapsed or refractory (“r/r”) B-cell lymphoma, and in June 2020 the National Medical Products Administration (“NMPA”) accepted for review its NDA relating to relma-cel as a third-line treatment for DLBCL. Relma-cel is expected to be the first CAR-T therapy to be approved as a Category 1 biologics product in China, and has potential to be a best-in-class CAR-T therapy.